ENG| |
Investor Relations

Creating Values and Growth

Financial Highlights

  • Revenue

  • Adjusted Profit Attributable to Shareholders

  • Adjusted EBITDA

  • Net Assets

  • Net Debts

  • Net Gearing Ratio

Year ended
31 March 2017
HK$’000
Year ended
31 March 2016
HK$’000
Change
Revenue
- Generic Drugs 1,097,574 944,753 +16.2%
- Proprietary Medicines 158,383 139,103 +13.9%
Total 1,255,957 1,083,856 +15.9%
Gross profit 556,888 487,755 +14.2%
Gross profit margin (%) 44.3% 45.0%
Profit attributable to shareholders of the Company 179,328 145,610 +23.2%
Profit margin attributable to shareholders of the Company (%) 14.3% 13.4%
Adjusted EBITDA (1) 328,918 261,197 +25.9%
Adjusted EBITDA margin (%) (2) 26.2% 24.1%
Return on equity (%) (3) 13.3% 15.6%

As at
31 March 2017
HK$’000
As at
31 March 2016
HK$’000
Change
Total assets 2,970,067 1,822,050 +63.0%
Total liabilities 1,197,749 865,905 +38.3%
Total equity 1,772,318 956,145 +85.4%

(1) Adjusted EBITDA is calculated based on adjusted earnings before interest, taxes, depreciation and amortisation, where “interest” is regarded as including interest income and interest expenses and “depreciation and amortisation” is regarded as including impairment losses on non-current assets. To arrive at adjusted EBITDA the Group’s earnings are further adjusted for non-recurring items not attributable to the operations of individual segments.
(2) Adjusted EBITDA margin is calculated based on adjusted EBITDA divided by revenue and multiplied by 100%.
(3) Return on equity is calculated based on profit for the year divided by the arithmetic mean of the opening and closing balances of total equity in the relevant year and multiplied by 100%.